Wednesday, 15 Aug 2018

You are here

Baricitinib Effective in SLE Trial

Dan Wallace and colleagues report in Lancet the results of a phase II study of the selective baricitinib, an oral selective Janus kinase (JAK1 and JAK2) inhibitor, in patients with systemic lupus erythematosus (SLE), demonstrating the efficacy and safety of JAK1/2 inhibition with baricitinib as a new potential oral therapy for SLE.

This randomised, placebo-controlled, 24-week trial enrolled 314 active (with skin or joint involvement), ANA+ or dsDNA+ SLE patients from in 11 countries to receive daily baricitinib 2 mg, or baricitinib 4 mg, or placebo. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K).

At week 24, an SLEDAI-2K arthritis or rash response was seen in 67% of baricitinib 4 mg, 58% of baricitinib 2 mg and 53% of placebo patients (4mg vs PBO; p=0·0414).  The SRI-4 response was also significant for the Bari 4 mg cohort only.

Adverse events were similar between groups and similar to that seen with baricitinib in the rheumatoid arthritis trials. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo.

This trial demonstrates the potential use of higher dose baricitinib therapy in uncontrolled SLE patients. Further studies must be done before JAK inhibition could be used to treat problematic lupus not controlled on standard or approved therapies. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

The patients haven't had good response to DMARDs or they are naaive? How about increased risk of thrombosis with JAK inhibitors in SLE especially with positive anti phospholipid serology?

More Like This

Ethnicity Matters in Sjogren's Syndrome

Among the ethnically diverse residents of Manhattan, certain groups had markedly different incidence rates of primary Sjogren's syndrome, a retrospective study found.

Women were more often affected, with age-adjusted incidence rates being highest for Asian women, at 10.5 (95% CI 6.6-15.7) per 100,000 person-years, according to Peter M. Izmirly, MD, of New York University School of Medicine in New York City, and colleagues.

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

Latin American Clinical Practice Guidelines for Lupus

The Annals of Rheumatic Disease have published the recently developed Latin American clinical practice guidelines for systemic lupus erythematosus (SLE) addressing the best pharmacologic interventions for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, hematological manifestations and the antiphospholipid syndrome.

Predicting Autoimmune Progression in ANA+ Patients

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.